The consensus among Wall Street analysts is currently a . While some analysts maintain a "Buy" rating, recent price targets suggest limited immediate upside. Current Stock Price: ~$14.81 (as of April 27, 2026).
The company is focusing on higher-margin generic launches and its innovative portfolio, including late-stage assets expected to complete enrollment in 2026. Market Cap: ~$17.25 billion as of April 2026. mylan stock buy or sell
The company expects 2026 to be a "pivotal year" with 2% revenue growth and $650 million in planned cost savings. The consensus among Wall Street analysts is currently a
Analysts are concerned about a lack of a clear growth strategy following an EBITDA "trough" expected in 2025 due to manufacturing issues. The company is focusing on higher-margin generic launches
To evaluate whether to "buy or sell," you must look at performance and analyst sentiment as of April 2026. Viatris (VTRS) Analyst Ratings & Price Targets (April 2026)
Technical analysis indicates a recent "sell signal" from a pivot top point reached in late April 2026. Financial Health & Outlook
Viatris is currently viewed as a value play or income stock rather than a high-growth candidate. Its low valuation and steady dividends may make it a "buy" for long-term holders, while short-term traders might "hold" or "sell" due to flat price targets and operational headwinds.